Disease

From Herceptin to Rozlytrek: how cancer drugs are getting more personalized

  • September, 25 2019
  • 136

In August 2019, the US FDA approved Roche’s Rozlytrek (entrectinib) for cancer patients whose solid tumors harbor a particular genetic mutation called NTRK. The approval comes more than 20 years after the very first ‘targeted’ breast cancer therapy reache

Disease

Tackling hypertension

  • September, 02 2019
  • 1124

Nearly one half of American adults suffer from hypertension, or high blood pressure. Globally, there are over 1 billion people with the disease – a figure that has doubled over the last 40 years. The World Health Organization estimates that hypertension c